Takeda Pharmaceuticals LLC and Pharmstandard JSC announced the start of their cooperation to localize the manufacturing of brentuximab vedotin, an innovative oncohematological drug, at the plant of Pharmstandard-UfaVITA OJSC.
The localization will allow not only to increase the availability of this drug for patients in Russia but, in the long term, will also reduce its cost. The first supplies of the drug from Pharmstandard-UfaVITA plant are scheduled for the end of Q1 2018.
“This is the company’s first innovative drug planned for localizing its manufacturing in Russia,” said Andrey Potapov, the General Director of Takeda Russia and Area Head of CIS. “Our main objective is to ensure the access of patients in Russia to innovative medicinal products of the company. Oncology area is a relatively new unit in Takeda Russia. But we are confident that advanced oncological drugs, which we can offer today to doctors and patients, will make a substantial contribution to the treatment of certain types of cancer and will significantly improve the quality of life of patients. We want to make them more affordable and work in a number of directions to achieve this, including the projects on risk sharing, localization, and clinical trials. Currently, Takeda Russia also continues its active efforts to localize other innovative products from the global portfolio, including at our own plant in Yaroslavl.”
The drug was registered in Russia in February 2016.